Fractyl Health has secured additional US patents covering the catheter, heating method and broader treatment claims behind Revita, its one-time endoscopic duodenal procedure intended to help patients maintain weight loss after discontinuing GLP-1 therapy. Protection now extends to 2042, ahead of a planned FDA De Novo marketing submission. The programme targets a central problem in metabolic medicine: weight regain once pharmacological appetite suppression ends.
Key Points
- New US patents extend Revita protection through 2042
- Claims cover catheter design, heating method and treatment scope
- Procedure targets weight maintenance after GLP-1 discontinuation
Longevity Analysis
Weight regain after GLP-1 withdrawal points to a durable issue in how the gut lining signals to metabolic and appetite-regulating pathways, rather than a failure of willpower or adherence. A one-time procedural intervention aimed at resetting duodenal signalling represents a different strategy from indefinite pharmacology — altering the source of the signal instead of continuously overriding it. Intellectual property runway matters here because it determines whether such approaches reach clinical availability at all, and metabolic durability remains one of the strongest determinants of long-term cardiovascular and functional outcomes.
Original published by Longevity.Technology, by Kyle Umipig.